Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND in untreated metastatic pancreatic ductal adenocarcinoma
ACTRN12621001290886Phase 2Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- May 2022
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of certepetide in pancreatic adenocarcinoma (PDAC), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Progression-free survival. Started May 2022; status: completed.
02
Drugs
certepetide
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ACTRN12621001290886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001290886.